Lead Discovery, AstraZeneca in discovery deal
AstraZeneca plc (LSE:AZN; NYSE:AZN) and Lead Discovery Center GmbH (Dortmund, Germany) partnered to discover and develop compounds under a two-year deal. AstraZeneca will add 250,000 of its compounds to Lead Discovery's internal screening project, and Lead Discovery will identify compounds that show activity against targets it selects in oncology, neuroscience, respiratory, inflammation, cardiovascular, gastrointestinal and infection indications. AstraZeneca said it will support assay development, screening and target validation activities at Lead Discovery, which will optimize the most promising compounds into leads with in vivo proof of concept. The pharma will have a first right of negotiation for development and commercialization of the compounds. ...